Continuation of Menopausal Hormone Therapy During Abnormal Cervical Cytology Evaluation
Systemic menopausal hormone therapy (HRT) is not a contraindication to cervical cancer screening or diagnostic evaluation of an abnormal Pap smear. HRT should be discontinued when a contraindication develops, including diagnosis of breast cancer or when bleeding requires cancer pathway assessment. [1], [2]
Medication Continuation During Pap Smear Diagnostic Workup
HRT should generally be continued during cervical cytology evaluation because HRT is not used to treat cervical lesions and is not listed as a driver of altered cervical cancer referral or management in suspected-cancer pathways. Management decisions during HRT should instead focus on symptoms such as unscheduled vaginal bleeding and on cancer diagnoses. [2], [1]
Circumstances Requiring HRT Discontinuation
Systemic HRT should be stopped when breast cancer is diagnosed. [1] Systemic HRT should be reassessed during unscheduled vaginal bleeding that is not within expected early adjustment windows and that requires prompt medical assessment. [1] For endometrial cancer concern, suspected-cancer referral should be used when unexplained post-menopausal bleeding cannot be attributed to HRT. [2]
Bleeding-Based Triggers During HRT
Vaginal bleeding is expected as a common side effect during the first 6 months of taking systemic HRT. Vaginal bleeding is also expected within 3 months of changing the dose or preparation of systemic HRT. [1] Unscheduled vaginal bleeding beyond these timeframes should prompt medical help. [1]
Endometrial Cancer Evaluation Interlocks With HRT
Endometrial cancer pathway referral is recommended for women (and trans men and non-binary people with female reproductive organs) aged 55 years and older with unexplained post-menopausal bleeding that cannot be attributed to HRT. [2] Endometrial cancer pathway referral is also recommended for women (and trans men and non-binary people with female reproductive organs) aged under 55 years with unexplained post-menopausal bleeding that cannot be attributed to HRT. [2]
Distinguishing Cervical Findings From HRT-Related Indications
Abnormal Pap smear evaluation is directed toward cervical pathology using cervical cancer pathways. [2] HRT discontinuation decisions are directed toward hormone-related contraindications and bleeding that cannot be attributed to HRT, which primarily affects endometrial cancer assessment rather than cervical cytology. [2], [1]
Common Clinical Pitfalls to Avoid
HRT should not be stopped automatically solely because of abnormal cervical cytology results. HRT discontinuation should be linked to a contraindication such as breast cancer diagnosis or to bleeding patterns that require endometrial cancer pathway evaluation when not attributable to HRT. [1], [2]
Monitoring and Reassessment After Any HRT Change
Stopping HRT can be done through gradual dose reduction or immediate cessation based on patient choice. [1] After any HRT-related bleeding event requiring assessment, reassessment should occur promptly when bleeding is unscheduled and beyond expected timeframes. [1]